TRCT
ACXP icon

Tower Research Capital (TRC)’s Acurx Pharmaceuticals ACXP Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.25K Buy
2,744
+1,713
+166% +$3.56K ﹤0.01% 4412
2026
Q1 		$3.83K Sell
1,031
-1,854
-64% -$5.26K ﹤0.01% 4262
2025
Q4 		$7.18K Buy
2,885
+1,808
+168% +$8.67K ﹤0.01% 4031
2025
Q3 		$4.62K Buy
1,077
+869
+418% +$5.24K ﹤0.01% 4320
2025
Q2 		$2.12K Sell
208
-13
-6% -$105 ﹤0.01% 4695
2025
Q1 		$1.72K Sell
221
-1
-0.5% -$13 ﹤0.01% 4662
2024
Q4 		$3.62K Buy
222
+119
+116% +$3.58K ﹤0.01% 4625
2024
Q3 		$3.92K Sell
103
-104
-50% -$4.4K ﹤0.01% 4736
2024
Q2 		$9.31K Buy
207
+64
+45% +$2.81K ﹤0.01% 4265
2024
Q1 		$7.03K Buy
+143
New +$9.29K ﹤0.01% 4276
2023
Q4 		– Sell
-355
Closed -$10.6K – 5907
2023
Q3 		$10.6K Buy
355
+133
+60% +$5.09K ﹤0.01% 4089
2023
Q2 		$11.8K Buy
222
+77
+53% +$4.59K ﹤0.01% 3930
2023
Q1 		$10K Hold
145
– – ﹤0.01% 4315
2022
Q4 		$12K Hold
145
– – ﹤0.01% 3667
2022
Q3 		$9K Buy
145
+57
+65% +$4.27K ﹤0.01% 4627
2022
Q2 		$7K Sell
88
-78
-47% -$5.25K ﹤0.01% 4754
2022
Q1 		$11K Buy
+166
New +$13K ﹤0.01% 4136
2021
Q4 		– Sell
-35
Closed -$4K – 6092
2021
Q3 		$4K Buy
35
+12
+52% +$1.24K ﹤0.01% 4947
2021
Q2 		$3K Buy
+23
New +$3.08K ﹤0.01% 4897

Other funds holding ACXP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Tower Research Capital (TRC)'s ACXP Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Acurx Pharmaceuticals (ACXP) stake by 166% in Q2 2026, buying an estimated $3.56K and bringing the position to 2,744 shares worth $4.25K. The position accounts for ﹤0.01% of the portfolio, ranked #4412.

Tower Research Capital (TRC) first reported a position in ACXP in Q2 2021 and has held it in 19 quarters since. The position peaked at $12K in Q4 2022. 19 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

  • Tower Research Capital (TRC) held 2,744 shares of Acurx Pharmaceuticals worth $4.25K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,713 Acurx Pharmaceuticals shares in Q2 2026, an estimated $3.56K.
  • Acurx Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4412 holding.
  • Tower Research Capital (TRC) first reported a position in Acurx Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Acurx Pharmaceuticals position peaked at $12K in Q4 2022.
  • 19 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.